纯度
≥ 95 % as determined by SDS-PAGE.
内毒素
< 0.1 EU/μg of the protein by LAL method.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
描述
Recombinant Human CCL18/PARC Protein is produced by Yeast expression system. The target protein is expressed with sequence (Ala21-Ala89) of human CCL18/PARC (Accession #NP_002979.1) fused with no tag .
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
（1）未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周；
（2）干粉蛋白复溶浓度建议在0.1-0.5 mg/mL，不能低于0.1mg/mL，长期储存请添加保护剂（如0.1%BSA），并分装保存，避免反复冻融；
（3）液体蛋白的保存温度及效期请参考说明书，如对液体蛋白浓度有要求，请提前咨询销售或者技术支持。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！
CCL18 is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Proof showed high levels of CCL18 in the serum of epithelial ovarian carcinoma patients suggesting its potential as a circulating biomarker. CCL18 chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. (CCL18) is predominantly secreted by M2-tumor associated macrophages (TAMs) and promotes malignant behaviors of various human cancer types. CCL18 has a correlation with cardiac function in patients with AAMI and it might be considered as an indicator of poor LVEF in patients with AAMI. Circulating and WAT-secreted CCL18 correlates with insulin resistance and metabolic risk score. Because CCL18 is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation. Macrophages are thought to be the main source of CCL18, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18 in macrophages warrants investigation.
